Last reviewed · How we verify

NCT04376073: ANNIE

Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer

Status unknown Phase 2 Last updated 25 November 2020
What this trial tests

Phase 2 trial testing Niraparib in Platinum-resistant Ovarian Cancer in 40 participants. Status unknown.

Timeline
22 May 2020
Primary endpoint
31 December 2021
31 March 2022

Quick facts

Lead sponsorJihong Liu
PhasePhase 2
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment40
Start date22 May 2020
Primary completion31 December 2021
Estimated completion31 March 2022
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Jihong Liu

Who can join

Adults 18 to 70, female only, with Platinum-resistant Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

At present, the standard treatment for platinum-resistant ovarian cancer patients is platinum-free chemotherapy, with poor efficacy and tolerance. The combination of anti-angiogenic drugs and PARPi can play a synergistic anti-tumor role and achieve good efficacy in platinum-sensitive recurrent ovarian cancer. This study intends to explore the safety and effectiveness of anlotinib and niraparib dual therapy in patients with platinum-resistant recurrent ovarian cancer, fallopian tube cancer, and primary peritoneal cancer (ovarian cancer).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence.
    Wang Q, Peng H, Qi X, Wu M, et al · · 2020 · cited 114× · PMID 32728057 · DOI 10.1038/s41392-020-0199-6
  2. Synthetic Lethality in Ovarian Cancer.
    Chandrasekaran A, Elias KM. · · 2021 · cited 34× · PMID 34518297 · DOI 10.1158/1535-7163.mct-21-0500
  3. A novel combination of niraparib and anlotinib in platinum-resistant ovarian cancer: Efficacy and safety results from the phase II, multi-center ANNIE study.
    Liu G, Feng Y, Li J, Deng T, et al · · 2022 · cited 25× · PMID 36583171 · DOI 10.1016/j.eclinm.2022.101767
  4. Overcoming the challenges of drug development in platinum-resistant ovarian cancer.
    Eskander RN, Moore KN, Monk BJ, Herzog TJ, et al · · 2023 · cited 24× · PMID 37916177 · DOI 10.3389/fonc.2023.1258228
  5. Efficacy evaluation of multi-immunotherapy in ovarian cancer: From bench to bed.
    Hu X, Bian C, Zhao X, Yi T. · · 2022 · cited 19× · PMID 36275669 · DOI 10.3389/fimmu.2022.1034903
  6. How to win the ovarian cancer stem cell battle: destroying the roots.
    Takahashi A, Hong L, Chefetz I. · · 2020 · cited 13× · PMID 35582216 · DOI 10.20517/cdr.2020.93
  7. An In-Depth Review of Niraparib in Ovarian Cancer: Mechanism of Action, Clinical Efficacy and Future Directions.
    Akay M, Funingana IG, Patel G, Mustapha R, et al · · 2021 · cited 12× · PMID 34363200 · DOI 10.1007/s40487-021-00167-z
  8. Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated Setting.
    Maiorano MFP, Maiorano BA, Biancofiore A, Cormio G, et al · · 2023 · cited 9× · PMID 37765068 · DOI 10.3390/ph16091261

Verify or expand the search:

Other trials of Niraparib

Trials testing the same drug.

Other recruiting trials for Platinum-resistant Ovarian Cancer

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04376073.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing